Abstracts tagged "practice guidelines"

Abstract Number: 2037 • 2017 ACR/ARHP Annual Meeting
HLA-B27 Testing in Patients >= 45 Years of Age and Subsequent Diagnosis of Late Onset Spondyloarthritis
Marc W. Nolan^1,2, Morgan M. Brown³ and Elie Gertner^1,2, ¹Section of Rheumatology, Regions Hospital, St. Paul, MN, ²Division of Rheumatology, University of Minnesota Medical School, Minneapolis, MN, ³HealthPartners Institute, St. Paul, MN
Background/Purpose: In 2015, the Canadian Rheumatology Association published their Choosing Wisely recommendations regarding HLA-B27 testing. One of the criteria that triggers testing is inflammatory back…
Abstract Number: 2734 • 2017 ACR/ARHP Annual Meeting
A Comparison of Current Practice to New Vasculitis Treatment Guidelines
Ishrat Gill¹, Norman Madsen², Imran Hassan³ and Elaine Yacyshyn⁴, ¹Medicine, University of Alberta, Sherwood Park, AB, Canada, ²Medicine, Rheumatology, University of Alberta, Edmonton, AB, Canada, ³EPICORE Centre, University of Alberta, Edmonton, AB, Canada, ⁴Medicine, University of Alberta, Edmonton, AB, Canada
Background/Purpose: Appropriate treatment for Anti-Neutrophilic Cytoplasm Antibodies (ANCA) Associated Vasculitis (AAV) requires induction and maintenance of remission, while balancing side effects from treatment. The CanVasc…
Abstract Number: 1491 • 2015 ACR/ARHP Annual Meeting
Effects of Drug Induced Toxicity on Patient Reported Outcomes in Early Rheumatoid Arthritis Treated-to-Target Using Conventional Triple DMARD Therapy
Nasir Wabe¹, Michael Sorich², Mihir Wechalekar^2,3, Leslie Cleland³, Leah McWilliams³, Anita Lee^4,5, Llew Spargo⁴, Robert Metcalf³, Cindy Hall⁴, Susanna Proudman^4,5 and Michael D. Wiese⁶, ¹School of Pharmacy and Medical Sciences and Sansom Institute for Health Research, University of South Australia, Adelaide, Australia, ²Flinders University, Adelaide, Australia, ³Royal Adelaide Hospital, Adelaide, Australia, ⁴Rheumatology Unit, Royal Adelaide Hospital, Adelaide, Australia, ⁵Discipline of Medicine, University of Adelaide, Adelaide, Australia, ⁶University of South Australia, Adelaide, Australia
Background/Purpose: While the introduction of the treat-to-target (T2T) strategy is associated with lower disease activity scores in rheumatoid arthritis (RA), the potential for increased toxicity…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].